Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats

Journal of Applied Physiology

Volumn 83, Issue 4, 1997, Pages 1209-1215

  Hill, Nicholas S ^a,b   Warburton, Rod R ^a   Pietras, Linda ^a   Klinger, James R ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Natriuretic peptides

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART VENTRICLE PRESSURE; INFLAMMATION; LUNG VASOCONSTRICTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

EID: 0030862759     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1997.83.4.1209     Document Type: Article

References (30)

1. Butler, W. H., A. R. Mattocks, and J. M. Barnes. Lesions in the liver and lung of rats given pyrrole derivatives of pyrrolizidine alkaloids. J. Pathol. 100: 169-175, 1970.
2. Chen, S.-J., Y.-F. Chen, Q. Meng, J. Durand, V. S. Dicarlo, and S. Oparil. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol. 79: 2122-2131, 1995.
3. Clozel, M., V. Breu, K. Burri, J.-M. Cassal, W. Fischli, G. A. Gray, H. Hirth, B. M. Loffler, M. Mueller, W. Neidhart, and H. Ramus. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365: 759-761, 1993.
4. Clozel, M., V. Breu, G. A. Gray, B. Lakine, B. M. Loffler, K. Burri, J. M. Cassal, G. Hirth, M. Miller, W. Neidhart, and H. Ramne. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 228-235, 1994.
5. B receptor mediates both vasodilation and vasoconstriction in vivo. Biochem. Biophys. Res. Commun. 186: 867-873, 1992.
6. Elton, T. S., S. Oparil, G. R. Taylor, P. H. Hicks, R. H. Young, H. Jin, and Y. F. Chen. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am. J. Physiol. 263 (Regulatory Integrative Comp. Physiol. 32): R1260-R1264, 1992.
7. Giaid, A., M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy, H. Shennib, S. Kimura, T. Masaki, W. P. Duguid, and D. J. Stewart. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328: 1732-1739, 1993.
8. Gillespie, M. N., W. B. Frederick, R. J. Altiere, J. W. Olson, and E. C. Kimmel. Pulmonary mechanical, ventilatory, and gas exchange abnormalities in rats with monocrotaline-induced pulmonary hypertension. Exp. Lung Res. 8: 191-199, 1985.
9. Hasunuma, K., D. M. Rodman, R. F. O'Brien, and I. F. McMurtry. Endothelin 1 causes pulmonary vasodilation in rats. Am. J. Physiol. 259 (Heart Circ. Physiol. 28): H48-H54, 1990.
10. Hess, P., M. Clozel, and J. P. Clozel. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J. Appl. Physiol. 81: 1027-1032, 1996.
11. Hill, N. S., P. Jederlinic, and J. Gagnon. Supplemental oxygen reduces right ventricular hypertrophy in monocrotaline-injected rats. J. Appl. Physiol. 66: 1642-1648, 1989.
12. Hilliker, K. S., T. G. Bell, D. Lorimer, and R. A. Roth. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. Am. J. Physiol. 246 (Heart Circ. Physiol. 15): H747-H753, 1984.
13. Hilliker, K. S., and R. A. Roth. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydralazine, dexamethasone or sulphinpyrazone. Br. J. Pharmacol. 82: 375-380, 1984.
14. Hilliker, K. S., and R. A. Roth. Increased vascular responsiveness in lungs of rats with pulmonary hypertension induced by monocrotaline pyrrole. Am. Rev. Respir. Dis. 131: 46-50, 1985.
15. Janakidevi, K., M. A. Fisher, P. J. DelVecchio, C. Tiruppathi, J. Figge, and A. B. Malik. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am. J. Physiol. 263 (Cell Physiol. 32): C1295-C1301, 1992.
16. Levin, E. R. Endothelins. N. Engl. J. Med. 333: 356-363, 1995.
17. Li, H. B., T. S. Elton, Y. F. Chen, and S. Oparil. Increased endothelin receptor gene expression in hypoxic rat lung. Am. J. Physiol. 266 (Lung Cell. Mol. Physiol. 10): L553-L560, 1994.
18. Loffler, B. M., V. Breu, and M. Clozel. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett. 333: 108-110, 1993.
19. Meyrick, B., W. Gamble, and L. Reid. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am. J. Physiol. 239 (Heart Circ. Physiol. 8): H692-H702, 1980.
20. Miyauchi, T., R. Yorikane, S. Sakai, T. Sakurai, M. Okada, M. Nishikibe, M. Yano, I. Yamaguchi, Y. Sugishita, and K. Goto. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. 73: 887-897, 1993.
21. Molteni, A., W. F. Ward, C. H. Ts'ao, C. D. Port, and N. H. Solliday. Monocrotaline-induced pulmonary endothelial dysfunction in rats (41847). Proc. Soc. Exp. Biol. Med. 176: 88-94, 1984.
22. Molteni, A., W. F. Ward, C. H. Ts'ao, and N. H. Solliday. Monocrotaline-induced cardiopulmonary damage in rats: Amelioration by the angiotensin-converting enzyme inhibitor CL-242817 (42370) (Abstract). Proc. Soc. Exp. Biol. Med. 182: 483, 1986.
23. Oparil, S., S. J. Chen, Q. C. Meng, T. S. Elton, M. Yano, and Y. F. Chen. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am. J. Physiol. 268 (Lung Cell. Mol. Physiol. 12): L95-L100, 1995.
24. Plestina, R., and H. B. Stoner. Pulmonary oedema in rats given monocrotaline pyrrole. J. Path. 106: -248, 1972.
25. Sobin, S. S., H. M. Tremer, J. D. Hardy, and H. P. Chiodi. Changes in arteriole in acute and chronic hypoxic pulmonary hypertension and recovery in rat. J. Appl. Physiol. 55: 1445-1455, 1983.
26. Stelzner, T. J., R. F. O'Brien, M. Yanagisawa, T. Sakurai, K. Sato, S. Webb, M. Zamora, I. F. McMurtry, and J. H. Fisher. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. J. Physiol. 262 (Lung Cell. Mol. Physiol. 6): L614-L620, 1992.
27. Stewart, D. J., R. D. Levy, P. Cernacek, and D. Langleben. Increased plasma endothelin1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114: 464-469, 1991.
28. Sugita, T., T. M. Hyers, I. M. Dauber, W. W. Wagner, I. F. McMurtry, and J. T. Reeves. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J. Appl. Physiol. 161: 371-374, 1983.
29. Warner, T. D. Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. Eur. Heart J. 4, Suppl. 1: 42-47, 1993.
30. Yanagisawa, M., H. Kurihara, S. Kumura, Y. Tomobe, M. Kobayashi, Y. Mitsui, K. Goto, and T. Masaki. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.